Crescentis Capital Limited reported a net loss of ₹252.63 lakh for the financial year ended March 31, 2026, narrowing from a loss of ₹542.24 lakh in the previous year. The board approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. Additionally, the board approved a proposal to raise funds up to ₹80 crore through a rights issue of fully paid-up equity shares. The company confirmed that its statutory auditors, M/s. D.S. Talwar & Co., Chartered Accountants, have issued an audit report with an unmodified opinion for the financial year ended March 31, 2026.

Financial Performance

The company reported total revenue from operations of ₹148.38 lakh for FY26, compared to negative revenue of ₹302.48 lakh in FY25. Total income for the year stood at ₹154.60 lakh. Total expenses increased to ₹474.97 lakh from ₹279.68 lakh in the previous year. The basic and diluted earnings per share (EPS) for FY26 was a loss of ₹1.57, improving from a loss of ₹4.48 in FY25.

Rights Issue Proposal

Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations and Chapter III of the SEBI ICDR Regulations, the board considered a proposal for raising funds up to an aggregate amount of ₹80 crore. The funds will be raised by way of issue of fully paid-up equity shares of ₹10 each to eligible equity shareholders on a rights basis. The record date for the rights issue will be announced later. The board constituted a Fund Raising Committee to finalize the terms, including the rights entitlement ratio and issue price.

Operational Highlights

For the year ended March 31, 2026, the company recognized an unrealized loss of ₹485.47 lakh due to adverse movements in market prices of its equity investments. The company successfully concluded a previous rights issue in July 2025, raising ₹4,903.91 lakh through the issuance of 70,05,579 equity shares at ₹70 per share. The proceeds were fully utilized during the year for the stated objects. The company also introduced the Crescentis Capital Limited Employees Stock Option Scheme, 2025, approved by shareholders in December 2025.

Crescentis Capital Limited has approved the re-appointment of its Managing Director and Whole-Time Director & CEO for a further term of five years starting September 12, 2026. The board's decision, taken on May 29, 2026, follows the recommendation of the Nomination and Remuneration Committee. These re-appointments are subject to the approval of shareholders at the ensuing general meeting and other statutory approvals.

Mr. Subba Rao Veera Venkata Meka has been re-appointed as Managing Director. His current term concludes at the close of business hours on September 11, 2026. Mr. Bhavanam Ruthvik Reddy has been re-appointed as Whole-Time Director & Chief Executive Officer, with his current term also ending on September 11, 2026. Both directors will serve for a period of five years from September 12, 2026.

The disclosure confirms there are no inter-se relationships between Mr. Subba Rao Veera Venkata Meka and other board members or senior management. However, Mr. Bhavanam Ruthvik Reddy is related to Mr. Bhaskara Rao Bollineni.

Director Profiles

Mr. Subba Rao Veera Venkata Meka brings over four decades of experience in domestic and international banking. He previously worked with Syndicate Bank, ABN AMRO, and The Royal Bank of Scotland (RBS). Since joining Crescentis Capital as Managing Director in September 2023, he has steered the company's transition from an investment-holding entity to an active Non-Banking Financial Company (NBFC).

Mr. Bhavanam Ruthvik Reddy holds a B.Tech in Civil Engineering and has over nine years of experience in business strategy and financial services. He has been associated with Krishna Institute of Medical Sciences (KIMS) since 2017. Serving as Whole-Time Director & CEO since September 12, 2023, he played a key role in commencing the company's NBFC operations in June 2025.

Re-appointment Details